Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 8Tumor-Agnostic 4CNS 4Genitourinary 3Gastrointestinal 3Breast 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 156Nivolumab 131Ipilimumab 76Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 19Opdualag 19Radiosurgery 18encorafenib 17aldesleukin 17CTLA-4 Antigen 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Restraint, Physical × Dermatologic × 1 year × Clear all
NCT04990726 2026-02-27

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

M.D. Anderson Cancer Center

Active not recruiting
126 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡